Padeliporfin VTP
Vascular Targeted Photodynamic therapy

Padeliporfin VTP is a novel Oncology technology platform with the potential to treat a range of solid tumors at localized and metastatic stages


ImPact Biotech is at the forefront of the biotechnology industry working to develop precise, safe & effective, and convenient new therapeutic solutions which will allow thousands of patients to confidently face the challenges of cancer while maintaining their quality of life.
Our technology – VTP – offers surgery-like efficacy where surgery is debilitating or where the patient is ineligible.

News feed
Interview with Dr Jonathan Coleman; Тhe ENLIGHTED Study PI discusses the study and potential for Light Activated Treatment of Upper Tract Urothelial Cancer
Read more
ImPact Biotech (ex Steba Biotech) treats first patient in pivotal ENLIGHTED study of Padeliporfin VTP
Read more
ImPact Biotech (ex Steba Biotech) receives FDA Orphan Drug Designation for Padeliporfin VTP in UTUC
Read more
FDA Grants Fast Track Designation to Padeliporfin ImPACT for ImPact Biotech (ex Steba Biotech)
Read more
Science – Padeliporfin VTP
To learn more about our novel Oncology platform and see our development pipeline
Transforming the treatment paradigm requires innovation and strong collaborations. If you share our vision and are interested in working with ImPact Biotech

“The prospect of bringing this revolution in the management of localized solid tumors to physicians and patients across the world is extremely exciting.” .

Barak Palatchi, CEO of ImPact biotech